Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model

Carla De Giovanni, Giordano Nicoletti, Lorena Landuzzi, Arianna Palladini, Pier-Luigi Lollini, Patrizia Nanni

Research output: Contribution to journalReview article

Abstract

The TS/A cell line was established in 1983 from a spontaneous mammary tumor arisen in an inbred BALB/c female mouse. Its features (heterogeneity, low immunogenicity and metastatic ability) rendered the TS/A cell line suitable as a preclinical model for studies on tumor-host interactions and for gene therapy approaches. The integrated biological profile of TS/A resulting from the review of the literature could be a path towards the description of a precision experimental model of mammary cancer.

Original languageEnglish
Pages (from-to)1-20
Number of pages20
JournalCancers
Volume11
Issue number12
DOIs
Publication statusPublished - Nov 27 2019

Keywords

  • TS/A
  • murine mammary cancer
  • preclinical model
  • gene therapy
  • metastases
  • immunotherapy

Cite this

Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model. / De Giovanni, Carla; Nicoletti, Giordano; Landuzzi, Lorena; Palladini, Arianna; Lollini, Pier-Luigi; Nanni, Patrizia.

In: Cancers, Vol. 11, No. 12, 27.11.2019, p. 1-20.

Research output: Contribution to journalReview article

De Giovanni, Carla ; Nicoletti, Giordano ; Landuzzi, Lorena ; Palladini, Arianna ; Lollini, Pier-Luigi ; Nanni, Patrizia. / Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model. In: Cancers. 2019 ; Vol. 11, No. 12. pp. 1-20.
@article{fc72e739810d4704a2add61ca86cb3bf,
title = "Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model",
abstract = "The TS/A cell line was established in 1983 from a spontaneous mammary tumor arisen in an inbred BALB/c female mouse. Its features (heterogeneity, low immunogenicity and metastatic ability) rendered the TS/A cell line suitable as a preclinical model for studies on tumor-host interactions and for gene therapy approaches. The integrated biological profile of TS/A resulting from the review of the literature could be a path towards the description of a precision experimental model of mammary cancer.",
keywords = "TS/A, murine mammary cancer, preclinical model, gene therapy, metastases, immunotherapy",
author = "{De Giovanni}, Carla and Giordano Nicoletti and Lorena Landuzzi and Arianna Palladini and Pier-Luigi Lollini and Patrizia Nanni",
year = "2019",
month = "11",
day = "27",
doi = "10.3390/cancers11121889",
language = "English",
volume = "11",
pages = "1--20",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI AG",
number = "12",

}

TY - JOUR

T1 - Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model

AU - De Giovanni, Carla

AU - Nicoletti, Giordano

AU - Landuzzi, Lorena

AU - Palladini, Arianna

AU - Lollini, Pier-Luigi

AU - Nanni, Patrizia

PY - 2019/11/27

Y1 - 2019/11/27

N2 - The TS/A cell line was established in 1983 from a spontaneous mammary tumor arisen in an inbred BALB/c female mouse. Its features (heterogeneity, low immunogenicity and metastatic ability) rendered the TS/A cell line suitable as a preclinical model for studies on tumor-host interactions and for gene therapy approaches. The integrated biological profile of TS/A resulting from the review of the literature could be a path towards the description of a precision experimental model of mammary cancer.

AB - The TS/A cell line was established in 1983 from a spontaneous mammary tumor arisen in an inbred BALB/c female mouse. Its features (heterogeneity, low immunogenicity and metastatic ability) rendered the TS/A cell line suitable as a preclinical model for studies on tumor-host interactions and for gene therapy approaches. The integrated biological profile of TS/A resulting from the review of the literature could be a path towards the description of a precision experimental model of mammary cancer.

KW - TS/A

KW - murine mammary cancer

KW - preclinical model

KW - gene therapy

KW - metastases

KW - immunotherapy

U2 - 10.3390/cancers11121889

DO - 10.3390/cancers11121889

M3 - Review article

C2 - 31783695

VL - 11

SP - 1

EP - 20

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 12

ER -